NEW YORK (GenomeWeb) – T2 Biosystems has entered into a $50 million debt facility agreement with CRG.

The firm will initially draw $40 million and can take out the rest through July 27, 2018, based on certain operating milestones.

T2 Bio said in a statement that it will use approximately $28 million to retire existing debt facilities and promissory notes. The remainder will be used for general corporate purposes, as working capital, and to fund strategic priorities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.